Properties of a "phase transition" induced by antiangiogenetic therapeutical protocols.
Inhibiting angiogenesis has been found to be an interesting therapeutical strategy against cancer. In fact, the success of tumor growth is subordinated to the corresponding increase of the vascular system feeding the neoplasm. However, optimization and design of proper antiangiogenetic therapeutical strategies is still an open problem. We apply a recently developed angiogenesis model to study how variations in the relevant parameters, e.g., induced by chemicals, may cause a "phase transition" to a region in the parameter space in which angiogenesis is not succesful. To demonstrate the reliability of our approach and its usefulness, we will study some specific drugs and use our model to investigate the influence of the main variables involved in a clinical treatment: the administration time, the duration of the drug effect, and the drug dose.
D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D055592:Biophysical Phenomena; D001703:Biophysics; D002455:Cell Division; D002471:Cell Transformation, Neoplastic; D006801:Humans; D008962:Models, Theoretical; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D013997:Time Factors
D020533:Angiogenesis Inhibitors